Document Type : Original Article

Authors

1 Gastroenterology and Hepatology Unit, Internal Medicine Department, Faculty of Medicine, Zagazig University, Zagazig, Egypt

2 Pathology Department, Faculty of Medicine, Zagazig University, Zagazig, Egypt

3 Clinical Oncology Department, Zagazig University, Zagazig, Egypt

4 General surgery department, Faculty of Medicine, Zagazig University, Zagazig, Egypt

5 Tropical Medicine Department, Zagazig University, Zagazig, Egypt

10.30476/mejc.2021.85085.1258

Abstract

Background: Colorectal cancer (CRC) is known to be the third most frequently diagnosed cancer and the fourth leading cause of cancer death worldwide. In Egypt, colorectal carcinoma is considered the 7th prevalent cancer, accounting for 3.47% of male cancers and 3% of female malignancies. A localized CRC can be entirely cured via surgical resection. Metastasis remains the leading cause of cancer mortality. IMP3 is an independent prognostic biomarker that expects metastasis and poor prognosis in the CRC. The upregulation of nuclear cyclin D1 plays an essential role in pathogenesis and metastases of CRC. We aimed to investigate the expression of IMP3 and cyclin D1 in colorectal carcinoma and their correlation with other clinicopathological features.
Method: In this retrospective cohort study, 80 formalin-fixed and paraffin-embedded blocks of CRC were obtained from the subjects. The immunohistochemical expression of IMP3 and cyclin D1 were examined and found to be correlated with clinical-pathological parameters and the outcome of the patients.
Results: Overexpression of IMP3 and cyclin D1 was noted in 68.75% and 56.25%, respectively. IMP3 expression was significantly correlated with tumor grade (P <0.001), TNM stage (P =0.040), and LVI (P= 0.005); cyclin D1 was significantly associated with TNM stage (P<0.001), LN metastasis (P<0.001), and DM (P =0.004); cyclin D1 was significantly correlated with TNM stage (P<0.001), LN metastasis (P<0.001), and DM (P= 0.004).
Conclusion: IMP3 and cyclin d1 were associated with poor prognosis in CRC, which makes them attractive targets for anticancer drug development.

Keywords

This article has been accepted for publication and undergone full peer review but has not been through the copyediting, typesetting, pagination, and proofreading process, which may lead to differences between this version and the Version of Record. Please cite this article as doi:10.30476/mejc.2021.85085.1258